Abstract
The ability of oral pefloxacin to penetrate into maxillary sinus cavity and nasal secretions was studied in 39 patients suffering from an exacerbation of chronic maxillary sinusitis. The mean levels of pefloxacin in sinus aspirate fluid 0, 3, 6, 9 and 12 h after the second oral dose of 400 mg were 2.30, 6.92, 3.74, 3.47 and 2.82 mg/l respectively. In sinus cystic fluid (macroscopically non-purulent) the mean pefloxacin levels were 2.30, 7.15, 4.20 and 4.15 mg/l respectively, and in nasal secretion 1.90, 9.05, 3.71, 3.20 and 2.85 mg/l respectively. The mean pefloxacin levels in serum obtained simultaneously were 1.50, 5.00, 3.10, 2.70 and 2.20 mg/l respectively. It is concluded that pefloxacin accumulates in inflamed sinus fluid at concentrations exceeding blood levels.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lundberg C, Engquist S Localization of bacteria and the cause of tissue destruction in maxillary sinusitis. Acta Otolaryngologica 1984, Supplement, 407: 30–32.
King A, Phillips I The comparative in vitro activity of pefloxacin. Journal of Antimicrobial Chemotherapy 1986, 17, Supplement B: 1–10.
Verbist L In vitro activity of pefloxacin against micro-organisms multiply resistant to beta-lactam antibiotics and aminoglycosides. Journal of Antimicrobial Chemotherapy 1986, 17, Supplement B: 11–17.
Auckenthaler R, Michea-Hamzehpour M, Perhere JC In vitro activity of newer quinolones against aerobic bacteria. Journal of Antimicrobial Chemotherapy 1986, 17, Supplement B: 29–39.
Fass RJ, Helsel VL In vitro antistaphylococcal activity of pefloxacin alone and in combination with other antistaphylococcal drugs. Antimicrobial Agents and Chemotherapy 1987, 31: 1457–1460.
Giamarellou H, Perdikaris G, Galanakis N, Davoulos G, Mandragos K, Sfikakis P Pefloxacin versus ceftazidime in the treatment of a variety of gram-negative bacterial infections. Antimicrobial Agents and Chemotherapy 1989, 33: 1362–1367.
Neu HC Quinolones in perspective. Journal of Antimicrobial Chemotherapy 1990, 26, Supplement B: 1–5.
Giamarellou H, Mandragos K, Bechrakis P, Rigas K, Bilalis D, Sfikakis P Pefloxacin versus imipenem in the therapy of nosocomial lung infections of intensive care unit patients. Journal of Antimicrobial Chemotherapy 1990, 26, Supplement B: 117–127.
Barry AL, Fuchs PC Antistaphylococcal activity of the fluoroquinolones CI-960, DP 131628, sparfloxacin, ofloxacin and ciprofloxacin. European Journal of Clinical Microbiology and Infectious Diseases 1991, 10: 168–171.
Hooper DC, Wolfson JS Bacterial resistance to the quinolone antimicrobial agents. American Journal of Medicine 1989, 87, Supplement 6C: 17–23.
Barre M, Houin G, Tillement JP Dose dependent pharmacokinetic study of pefloxacin a new antibacterial agent in humans. Journal of Pharmaceutical Sciences 1984, 73: 1379–1382.
Frydman AM, LeRoux Y, Lefervre MA, Djebbar F, Fourtillan JB, Gaillot J Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. Journal of Antimicrobial Chemotherapy 1986, 17, Supplement B: 65–79.
Charles L, Daley A, Merle S The runny nose: infection of the paranasal sinuses. Infectious Diseases Clinics of North America 1988, 2: 131–147.
Axelsson A, Brorson JE Concentration of antibiotics in sinus secretion. Doxycyline and spiramycin. Annals of Otology, Rhinology and Laryngology 1973, 82: 44–48.
Axelsson A, Brorson JE The concentration of antibiotics in sinus secretions. Ampicillin cephradine and erythromycin estolate. Annals of Otology, Rhinology and Laryngology 1974, 83: 323–330.
Lundberg C, Gullers K, Malbborg AS Antibiotics in sinus secretions. Lancet 1968, ii: 107.
Paavolainen M, Kohonen A, Palva T, Rendkonen VO Penetration of erythromycin stearate into maxillary sinus mucosa and secretion in chronic maxillary sinusitis. Acta Otolaryngologica 1977, 84: 292–295.
Dan M, Englander M, Corea A, Havel M, Berger AS Concentrations of ciprofloxacin in external ear granulation tissue and maxillary sinus mucosa. Reviews of Infectious Diseases 1989, 11, Supplement 5: 1080.
Zucher J, Jaehde U, Sorger F, Naberk K, Schumacher H, Kraus C, Schunack W Distribution of enoxacin and its main metabolite oxo-enoxacin into saliva, nasal secretions, tears and sweat of healthy volunteers. Reviews Infectious Diseases 1989, 11, Supplement 5: 1136.
Malmborg AS, Kumlien J, Samuelson A, Svennerus K Concentration of enoxacin in sinus secretions. Reviews Infectious Diseases 1989, 11, Supplement 5: 1205–1206.
Desnottes JF, Jacotot F, Bruel J, Bassoullet MT, Niel G Effects of pefloxacin on phagocytosis function of rat macrophages and polymorphonuclear leucocytes. Journal of Antimicrobial Chemotherapy, 1986, 17, Supplement B: 53–57.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Petrikkos, G., Goumas, P., Moschovakis, E. et al. Penetration of pefloxacin into maxillary sinus cavity and nasal secretions. Eur. J. Clin. Microbiol. Infect. Dis. 11, 828–831 (1992). https://doi.org/10.1007/BF01960883
Issue Date:
DOI: https://doi.org/10.1007/BF01960883